Breaking News

Janssen Licenses Biocytogen’s RenLite Platform

Antibodies assembled after RenLite discovery have a traditional antibody structure with properties that are advantageous for downstream CMC development.

Biocytogen Pharmaceuticals Co., Ltd. signed a non-exclusive license agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s RenLite platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain, and other biological ther...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters